ARTICLE | Clinical News
Realm's atopic dermatitis candidate misses in Phase II
August 17, 2018 3:15 AM UTC
Realm Therapeutics plc (LSE:RLM; NASDAQ:RLM) reported preliminary data from a Phase II trial in 122 patients with mild to moderate atopic dermatitis showing that PR022 missed the primary endpoint. Twice-daily topical PR022 for 28 days failed to significantly improve the percent change from baseline in Eczema Area and Severity Index (EASI) at day 29 vs. vehicle. The double-blind, U.S. trial evaluated 0.05% and 0.1% formulations of PR022.
PR022 is a topical gel formulation containing a high concentration of hypochlorous acid...
BCIQ Company Profiles